SCHEMBL19924284

SCHEMBL19924284

CCCC[C@H](CNC(C)=O)Nc1nc(NCc2ccc(OC)cc2OC)nc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 11/20 0.48
▸ CYP3A4 P08684 11/20 0.48
▸ CYP2C19 P33261 11/20 0.48
▸ TSHR P16473 10/20 0.48
▸ CYP2C9 P11712 10/20 0.48
▸ HSD17B10 Q99714 7/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ ALOX15 P16050 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ HIF1A Q16665 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ CYP2D6 P10635 9/20 0.48
▸ LMNA P02545 6/20 0.48
▸ MAPT P10636 4/20 0.48
▸ MEN1 O00255 7/20 0.47
▸ KMT2A Q03164 7/20 0.47
▸ USP2 O75604 6/20 0.47
▸ MAPK1 P28482 2/20 0.46
▸ HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19924285 1.00 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C19TSHRCYP2C9
SCHEMBL30076248 1.00 CYP1A2 (0.48) CYP1A2CYP3A4CYP2C19TSHRCYP2C9
SCHEMBL19924192 0.90 KCNH2 (0.46) CYP1A2CYP3A4CYP2C19TSHRCYP2C9
SCHEMBL19924193 0.90 KCNH2 (0.46) CYP1A2CYP3A4CYP2C19TSHRCYP2C9
SCHEMBL19924246 0.89 KCNH2 (0.42) CYP1A2CYP3A4CYP2C19TSHRCYP2C9
SCHEMBL19924247 0.89 KCNH2 (0.42) CYP1A2CYP3A4CYP2C19TSHRCYP2C9
SCHEMBL18109452 0.88 TLR8 (0.44) CYP1A2CYP3A4CYP2C19TSHRCYP2C9
SCHEMBL18109450 0.88 TLR8 (0.44) CYP1A2CYP3A4CYP2C19TSHRCYP2C9
SCHEMBL19924243 0.86 PDE4A (0.43) TSHRHSD17B10SMN1; SMN2MAPTMEN1
SCHEMBL19924245 0.86 PDE4A (0.43) TSHRHSD17B10SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522570-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2026-01-13 — — US disclosed
US-20240254091-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. 2024-08-01 — — US disclosed
US-11827609-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2023-11-28 — — US disclosed
US-11827609-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2023-11-28 — — US disclosed
CN-109923106-B toll-like receptor modulator compounds 吉利德科学公司 2022-09-13 — — CN disclosed
US-20220073473-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. 2022-03-10 — — US disclosed
EP-3507276-B1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES INC (US) 2021-11-03 — — EP disclosed
EP-3507276-B1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES INC (US) 2021-11-03 — — EP disclosed
US-11124487-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2021-09-21 — — US disclosed
US-11124487-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2021-09-21 — — US disclosed
US-10370342-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2019-08-06 — — US disclosed
US-10370342-B2 Toll like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2019-08-06 — — US disclosed
WO-2018045144-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2018-03-08 — — WO disclosed
US-20180065938-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. 2018-03-08 — — US disclosed
US-20180065938-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS GILEAD SCIENCES, INC. 2018-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073473-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS TLR8, TLR3, TLR6 CYP1A2 4638/4885CYP3A4 4333/4885CYP2C19 4715/4885
US-10370342-B2 Toll like receptor modulator compounds TLR8, TLR3, TLR6 CYP1A2 4638/4885CYP3A4 4333/4885CYP2C19 4715/4885
US-11124487-B2 Toll like receptor modulator compounds TLR8, TLR3, TLR6 CYP1A2 4638/4885CYP3A4 4333/4885CYP2C19 4715/4885
US-20240254091-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS TLR8, TLR3, TLR6 CYP1A2 4638/4885CYP3A4 4333/4885CYP2C19 4715/4885
US-20180065938-A1 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS TLR8, TLR3, TLR6 CYP1A2 4638/4885CYP3A4 4333/4885CYP2C19 4715/4885
US-11827609-B2 Toll like receptor modulator compounds TLR8, TLR3, TLR6 CYP1A2 4638/4885CYP3A4 4333/4885CYP2C19 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback